Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Family Medicine
Clinical Trials: Atherosclerosis
A listing of clinical trials currently looking for volunteers to enroll in Atherosclerosis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Birmingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fairhope : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Huntsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mobile : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Alaska
Anchorage : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Arizona
Bullhead City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Glendale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Phoenix : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Phoenix : St. Luke's Hospital-Phoenix
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Scottsdale : Scottsdale Healthcare Shea
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Arkansas
Hot Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jonesboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Little Rock : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Little Rock : Arkansas Heart Hospital
The OMEGA Clinical Trial
California
Santa Ana : Coastal Multi-Specialty Research
Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.
View More »
Carmichael : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Escondido : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fullerton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Huntington Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lancaster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Loma Linda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Long Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Los Angeles : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Los Angeles : University of Southern California
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Los Gatos : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mission Viejo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mountain View : Fogarty Clinical Research Inc./El Camino Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Newport Beach : Hoag Memorial Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Northridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oceanside : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orange : St. Joseph Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Orangevale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palm Spring : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palm Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pasadena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pomona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Redondo Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sacramento : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Diego : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Diego : Kaiser Foundation Hospital-San Diego
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
San Francisco : San Francisco Veterans Affairs Medical Center
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Santa Ana : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Clara : Abbott Vascular
The ABSORB BTK (Below The Knee) Clinical Investigation
Santa Rosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Temecula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Torrance : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Torrance : Los Angeles Biomedical Research Institute
Effect of Aged Garlic Extract on Atherosclerosis
Torrance : Harbor -UCLA Medical Center
The OMEGA Clinical Trial
Tustin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Visalia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vista : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Walnut Creek : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Colorado
Aurora : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Denver : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Longmount : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Delaware
Newark : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
District of Columbia
Washington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florida
Clearwater : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Daytona Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Defuniak Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Doral : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hollywood : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Jacksonville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jacksonville Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jupiter : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Miami : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Miami : Baptist Cardiac and Vascular Institute
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Miami Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Naples : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orlando : GSK Investigational Site
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment
Orlando : Florida Hospital
The OMEGA Clinical Trial
Pinellas Park : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Port Charlotte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Port Orange : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sarasota : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sarasota : Sarasota Memorial Hospital
The OMEGA Clinical Trial
South Miami : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tallahassee : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tampa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wellington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Georgia
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Atlanta : Piedmont Heart Institute
Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program
Augusta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austell : Wellstar Cobb Hospital
SuperNOVA Clinical Stenting Trial
Covington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cumming : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Decatur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gainesville : Northeast Georgia Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Macon : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roswell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hawaii
Honolulu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Honolulu : Hawaii Permanente Medical Group - Kaiser
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Idaho
Coeur D Alene : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Illinois
Chicago : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chicago : Northwestern University Memorial Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Chicago : Rush University Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Chicago : Northwestern University
Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Jerseyville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Lombard : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oak Lawn : Advocate Christ Medical Center
SuperNOVA Clinical Stenting Trial
Peoria : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Peoria : St. Francis Medical Center
SuperNOVA Clinical Stenting Trial
Springfield : St. John's Hospital and Memorial Medical Center/ Prairie Heart Cooperative
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Springfield : Southern Illinois University-Memorial Medical Center
The OMEGA Clinical Trial
Indiana
Anderson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Evansville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fort Wayne : Parkview Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Ft. Wayne : Parkview Hospital
SuperNOVA Clinical Stenting Trial
Indianapolis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Indianapolis : St. Vincent's Hospital
The OMEGA Clinical Trial
Iowa
Ames : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Waterloo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kansas
Kansas City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Overland Park : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Topeka : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wichita : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kentucky
Lexington : Central Baptist Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Lexington : St. Joseph Hospital
The OMEGA Clinical Trial
Louisville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Louisville : University of Louisville
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Owensboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Louisiana
Baton Rouge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Covington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Houma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lafayette : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mandeville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Metairie : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Orleans : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Orleans : Ochsner Clinic Foundation
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
New Orleans : Ochsner Clinic Foundation
SuperNOVA Clinical Stenting Trial
Opelousas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shreveport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slidell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Winnsboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zachary : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Maine
Beltsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Maryland
Towson : Spectrum Clinical Research, Inc.
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)
Towson : Spectrum Clinical Research, Inc.
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)
View More »
Baltimore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Baltimore : Johns Hopkins Bayview Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Baltimore : Sinai Center for Thrombosis Research
Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis
Baltimore : Frederick Memorial Hospital
SuperNOVA Clinical Stenting Trial
Baltimore : Union Memorial Hospital
The OMEGA Clinical Trial
Bethesda : Cardiovascular and Pulmonary Branch (CPB) of NIH
Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lutherville Timonium : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rockville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Massachusetts
Boston : Massachusetts General Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Boston : Massachusetts General Hospital
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Boston : Massachusetts General Hospital
Subclinical Atherosclerosis in HIV-infected Patients
Boston : Beth Israel Deaconess Medical Center
SuperNOVA Clinical Stenting Trial
Burlington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Fall River : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haverhill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hyannis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Michigan
Ann Arbor : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chelsea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Flint : McLaren Regional Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Kalamazoo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Midland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Novi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petoskey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petoskey : Northern Michigan Hospital
SuperNOVA Clinical Stenting Trial
Royal Oak : William Beaumont Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Royal Oak : William Beaumont Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Saginaw : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Troy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wyoming : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Minnesota
Duluth : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Duluth : St. Mary's Duluth Clinic Regional Heart Center
The OMEGA Clinical Trial
Edina : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Minneapolis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Robbinsdale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Rochester : Mayo Clinic
Assessment of Coronary Plaque Composition Using Optical Coherence Tomography
Rochester : Mayo Clinic
Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III
Saint Paul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Cloud : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Paul : Regions Hospital
The OMEGA Clinical Trial
Mississippi
Hattiesburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Picayune : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Missouri
Chesterfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kansas City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint Louis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Springfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
St. Louis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Louis : St. John's Mercy Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Nebraska
Grand Island : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lincoln : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Omaha : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Hampshire
Lebanon : Dartmouth Hitchcock Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Lebanon : Dartmouth Hitchcock Medical Center
SuperNOVA Clinical Stenting Trial
New Jersey
Camden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Camden : Our Lady of Lourdes Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Cherry Hill : Our Lady of Lourdes Medical Center
The OMEGA Clinical Trial
Freehold : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haddon Heights : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
New Brunswick : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ocean : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pomona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Mexico
Albuquerque : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Albuquerque : Presbyterian Hospital
The OMEGA Clinical Trial
New York
Albany : Albany Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Binghamton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Buffalo : Millard Fillmore Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Endwell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liverpool : St. Joseph's Hospital Health Center
SuperNOVA Clinical Stenting Trial
View More »
Mineola : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New York : Mount Sinai School of Medicine Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
New York : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New York : Lenox Hill Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
New York : Columbia Presbyterian Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
New York : NYU Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
New York : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
New York : Mount Sinai Medical Center
SuperNOVA Clinical Stenting Trial
Rochester : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rochester : University of Rochester-Strong Memorial Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Roslyn : St. Francis Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Williamsville : 115 Flint Road
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
North Carolina
Raleigh : Rex Healthcare
ALERTS (AngeLmed for Early Recognition and Treatment of STEMI) Study
Raleigh : Rex Healthcare
TRANSLATE- Treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Registry
View More »
Asheboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Calabash : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charlotte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charlotte : Mid-Carolina Cardiology Presbyterian Hospital
SuperNOVA Clinical Stenting Trial
Durham : Duke University Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Greensboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hickory : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pinehurst : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Raleigh : WakeMed Health and Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Raleigh : Wake Medical Center
The OMEGA Clinical Trial
Salisbury : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sanford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Statesville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tabor City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wilmington : New Hanover Regional Medical Center
SuperNOVA Clinical Stenting Trial
Winston Salem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Winston-Salem : Forsyth Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
North Dakota
Fargo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ohio
Akron : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cincinnati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cincinnati : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Cincinnati : The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital
The OMEGA Clinical Trial
Cincinnati : Good Samaritan Hospital
The OMEGA Clinical Trial
View More »
Cleveland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cleveland : Cleveland Clinic Foundation
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Columbus : Ohio State University
Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE)
Columbus : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbus : Riverside Methodist Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Columbus : Grant Medical Center
SuperNOVA Clinical Stenting Trial
Columbus : Ohio State University Medical Center
SuperNOVA Clinical Stenting Trial
Columbus : Ohio State University Medical Center
The OMEGA Clinical Trial
Marion : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Toledo : The Toledo Hospital
The OMEGA Clinical Trial
Toledo : Mercy St. Vincent Medical Center
The OMEGA Clinical Trial
Oklahoma
Bartlesville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oklahoma City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oklahoma City : Oklahoma Heart Hospital
The OMEGA Clinical Trial
Tulsa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oregon
Bend : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Oregon Health and Science University Stroke Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Pennsylvania
Abington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Allentown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Altoona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beaver : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beaver : Heritage Valley Health System
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Camp Hill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Harrisburg : Pinnacle Health Cardiovascular Insititute
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Hershey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Philadelphia : Thomas Jefferson University Hospital
The OMEGA Clinical Trial
Philidelphia : Presbyterian University of Pennsylvania Medical Center
The OMEGA Clinical Trial
Pittsburgh : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pittsburgh : University of Pittsburgh Medical Center (UPMC)
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Pittsburgh : University of Pittsburgh Physicians Division of Vascular Surgery/Shadyside Medical
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Pittsburgh : UPMC - Passavant
SuperNOVA Clinical Stenting Trial
Pottstown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tipton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Uniontown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wyomissing : St. Joseph's Medical Center/Berks Cardiologists
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Yardley : St. Mary Medical Center
The OMEGA Clinical Trial
York : York Hospital
SuperNOVA Clinical Stenting Trial
Rhode Island
Cumberland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Providence : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Carolina
Anderson : Anderson Area Medical Center
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
Anderson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charleston : Medical University of South Carolina Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Charleston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mt. Pleasant : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
N. Myrtle Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ninety Six : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orangeburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rock Hill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Varnville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Dakota
Rapid City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rapid City : Black Hills Cardiovascular
SuperNOVA Clinical Stenting Trial
Sioux Falls : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sioux Falls : North Central Heart Institute
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Tennessee
Germantown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Germantown : The Stern Cardiovascular Center/Methodist Germantown Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Johnson City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kingsport : Wellmont Holston Valley Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Knoxville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Knoxville : Mercy Medical West/Turkey Creek Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Knoxville : Mercy Medical Center West
SuperNOVA Clinical Stenting Trial
Nashville : St. Thomas Research Institute, LLC
SuperNOVA Clinical Stenting Trial
Texas
Allen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austin : Heart Hospital of Austin
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Beaumont : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bedford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brownsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Dallas : Veterans Affairs North Texas Health Care Systems
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Dallas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dallas : Presbyterian Hospital of Dallas
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Dallas : Dallas Veteran's Administration Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Dallas : VA North Texas Health Care System
SuperNOVA Clinical Stenting Trial
Gonzales : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Houston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Houston : St. Luke's Episcopal Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Houston : Baylor College of Medicine
Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions
Irving : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lake Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leander : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Livingston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lufkin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Marshall : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
McKinney : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Odessa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pasadena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Plano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Antonio : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Temple : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Waco : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Webster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Utah
Bountiful : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Layton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salt Lake City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vermont
Virginia
Burke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Danville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ettrick : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Falls Church : Inova Fairfax Hospital
SuperNOVA Clinical Stenting Trial
Norfolk : Chesapeake General Hospital/Sentara Norfolk General Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Richmond : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Richmond : St. Mary's Hospital / Virginia Cardiovascular Specilists
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Washington
Port Orchard : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Renton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seattle : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seattle : Swedish Medical Center
SuperNOVA Clinical Stenting Trial
Seattle : University of Washington Coronary Atherosclerosis Research Lab
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
View More »
Silverdale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Spokane : Deaconess Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Tacoma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Yakima : Yakima Heart Center
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
West Virginia
Wisconsin
Madison : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Madison : University of Wisconsin
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Milwaukee : St. Luke's Medical Center - Milwaukee
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Wauwatosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Argentina
Bahía Blanca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Buenos Aires : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Caba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Caba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cipolletti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cordoba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Córdoba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Corrientes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Formosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mar del Plata : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Posadas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Quilmes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rosario : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Luis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Miguel de Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Nicolas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Salvador de Jujuy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Fe : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santiago del Estero : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Australia
Bateman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Garran : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Geelong : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gosford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heidelberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Hobart : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Joondalup : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kogarah : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liverpool : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Melbourne : The Alfred
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
Milton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Perth : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Southport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austria
Feldbach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Graz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Linz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salzburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Stefan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Vienna : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vienne : Allgemeines Krankenhaus AKH
SuperNOVA Clinical Stenting Trial
Wien : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belgium
Aalst : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bonheiden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bonheiden : Imelda Ziekenhuis
SuperNOVA Clinical Stenting Trial
Bonheiden : Imelda Ziekenhuis
The OMEGA Clinical Trial
Brasschaat : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
De Pinte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dendermonde : AZ Sint-Blasius, Campus Dendermonde
SuperNOVA Clinical Stenting Trial
Genk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Genk : Ziekenhuis Oost Limburg
SuperNOVA Clinical Stenting Trial
Gent : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gent : Universitair Ziekenhuis Gent
The OMEGA Clinical Trial
Hasselt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hasselt : Virga Jesse Ziekenhuis
The OMEGA Clinical Trial
Huy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leuven : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mechelen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ottignies : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roeselare : H-Hartziekenhuis Roeselare-Menen vzw
The OMEGA Clinical Trial
Tienen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brazil
Belem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belo Horizonte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belo Horizonte : Hospital Felicio Rocho
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Blumenau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brasilia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Campinas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Campo Grande : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Curitiba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florianópolis : Clinica Coris Medicina Avançada /Baia Sul Medical Center
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Goiania : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Passo Fundo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pelotas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Porto Alegre : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Recife : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santo Andre : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sao Jose do Rio Preto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sao Paulo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sao Paulo : Heart Institute
Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
São Paulo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
São Paulo : Hospital Santa Marcelina de São Paulo
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
São Paulo : Irmandade Santa Casa de Misericórdia de São Paulo
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
São Paulo : Instituto Dante Pazzanese de Cardiologia
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Uberlândia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bulgaria
Pazardzhik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pleven : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Plovdiv : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sofia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Canada
Cambridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Drummondville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gatineau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Granby : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Guelph : Guelph General Hospital
SuperNOVA Clinical Stenting Trial
View More »
Halifax : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Joliette : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kitchener : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lachine : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Laval : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lévis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Longueuil : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Loretteville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mississauga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Montreal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Montreal : Hospital Maisonneuve-Rosemont
SuperNOVA Clinical Stenting Trial
Montreal : Innovaderm Research Inc
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Mount Pearl : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Westminster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Newmarket : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Peterborough : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Quebec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Québec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sainte-Foy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saskatoon : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Scarborough : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sherbrooke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ste-Foy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St-Jean-sur-Richelieu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Surrey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Thetford Mines : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Thunder Bay : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Toronto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Winnipeg : Winnipeg Health Sciences Centre
SuperNOVA Clinical Stenting Trial
China
Beijing : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beijing : Cardiology department ,Beijing Anzhen hospital
Fluvastatin AmelIorates aTHerosclerosis Study
Beijing : Chinese PLA General Hospital
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
Changsha : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hangzhou : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Nanjing : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shanghai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shanghai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tianjin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Colombia
Baranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Barranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Barranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bogotá : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucaramanga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cartagena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cartegena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florida Blanca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Floridablanca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Czech Republic
Benesov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Broumov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kladno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Louny : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Marianske lazne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Most : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ostrava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pardubice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Plzen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Prague 4 - Krc : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 11 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 2 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 2 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Praha 9 : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Semily : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slany : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Usti nad Labem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Usti nad Orlici : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vyskov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Znojmo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Denmark
Aarhus C : Dep. of Dermatology
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Estonia
Parnu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tallinn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Viljandimaa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Võru : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
France
Germany
Anderbeck : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bad : Kerckhoff Heart and Thoraxcenter
The OMEGA Clinical Trial
Bad Krozingen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bad Segeberg : Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH
The OMEGA Clinical Trial
Balve : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Berlin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Berlin : Center or Diagnostic Radiology and Minimally Invasive Therapy / Gefäßzentrum am JuedischenKrankenhaus
SuperNOVA Clinical Stenting Trial
Berlin : EV Krankenhaus Koningin Elisabeth
SuperNOVA Clinical Stenting Trial
Borna : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chemnitz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dillingen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dortmund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dresden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Duisburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Düsseldorf : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ebersbach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Elsterwerda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Erlangen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Essen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Falkensee : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Flensburg : Ev. Luth. Diakonissenanstalt Flensburg
SuperNOVA Clinical Stenting Trial
Frankfurt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Freiburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fulda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Giengen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haag : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Halle/'Saale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hamburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heidelberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heidelberg : Universitaetsklinikum Heidelberg
The OMEGA Clinical Trial
Heidenau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heilbronn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Herne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jerichow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kallstadt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kamp-Lintfort : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Koblenz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Köln : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kuenzing : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leipzig : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leipzig : Herzzentrum Leipzig GmbH/Park Krankenhaus
SuperNOVA Clinical Stenting Trial
Lichtenfels : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ludwigshafen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lüneburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mainz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mayen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Meissen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Muehldorf am Inn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Muehlhausen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mühlheim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Munich : Department of Neurology, TU Munich
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Münster : Universitätsklinikum Münster
Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)
Neuhofen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Neunkirchen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Northeim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nürnberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oelde : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oschatz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Paderborn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Potsdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rednitzhembach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Reinfeld : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rostock : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rotenburg a.d. Fulda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rüdersdorf : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Siegen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ulm : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wedel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Weinheim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wiesbaden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Witten : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wolmirstedt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greece
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Athens - GR : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chaidari : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chalikida : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heraklion : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Magoula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Patras : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Thessaloniki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Voula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Guatemala
Guatemala City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hungary
Budapest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Debrecen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gyula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kistarcsa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komarom : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Miskolc : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mosonmagyarovar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nyiregyháza : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pecs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Szeged : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Szentes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Veszprem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zalaegerszeg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Iceland
Kopavogur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Reykjavik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
India
Ahmedabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ahmedabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bangalore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bengaluru : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bikaner : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Chennai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Coimbatore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ghaziabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Guntur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hyderabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hyderabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jaipur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kochi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lucknow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ludhiana : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Madurai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Manipal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mohali : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nagpur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nashik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nellore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Delhi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Delhi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pune : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rajasthan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Secunderabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Surat : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tirupati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vadodara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Varanasi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vijayawada : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vishakhapatnam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Italy
Ancona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bergamo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brescia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Casorate Primo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Catanzaro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Chieti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cortona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fermo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Firenze : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Foggia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Massa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Milano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Monserrato : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Napoli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Novara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palermo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Parma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pavia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Piacenza : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pisa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pozzilli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Daniele Del Friuli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Maria Capua Vetere : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sassari : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Treviglio : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Verona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Veruno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Japan
Amagasaki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bunkyo-ku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chiyoda-ku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fujioka-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Funabashi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Higashiibaraki-gun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hitachi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ichinomiya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Itabashi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kasuga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komatsushima : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kumamoto City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kusatsu-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kyoto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Matsudo-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nagano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nagoya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nishinomiya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ogaki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ogura-gun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Osaka : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sendai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sendai-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takamatsu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takarazuka-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takasaki-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takatsuki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tokorozawa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Yokohama-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Korea, Republic of
Busan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Busan : Inje University Pusan Paik Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Daegu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Daegu : Yeungnam University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Daejeon : Chungnam National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
View More »
Daejon : Eulji University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Deagu : Kyungpook National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Gwangju : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gwangju : Chonnam National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Iksan : Wonkwang University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Inchon : Inha University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Pusan : Dong-A University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seoul : Kyung Hee University Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Seoul Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Eulji Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Asan Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Boramae Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Uijeongbu-Si : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wonju : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Latvia
Daugavplis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liepaja : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Riga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Riga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Riga : P. Stradins University Hospital
The OMEGA Clinical Trial
View More »
Ventspils : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lebanon
Beirut : Rafic Hariri University Hospital
Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis
Lithuania
Alytus : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kaunas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kedainiai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Klaipeda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Panevezys : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Siauliai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vilnius : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Netherlands
Alkmaar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amersfoort : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amstelveen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amsterdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amsterdam : Academic Medical Center
Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque
View More »
Amsterdamn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Apeldoorn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Breda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Den Haag : Haga Ziekenhuis locatie Leyweg
The OMEGA Clinical Trial
Deventer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Doetinchem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ede : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Eindhoven : Catharina Ziekenhuis
The OMEGA Clinical Trial
Gouda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Groningen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haarlem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heerlen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hoorn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leeuwarden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Maastricht : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Maastricht : Acadmisch Ziekehus
The OMEGA Clinical Trial
Meppel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nijmegen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rotterdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sneek : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tiel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Utrecht : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Venlo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Zealand
Auckland : Auckland City Hospital
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
Auckland : Ascot Angiography
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Auckland : Auckland City Hospital
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Auckland : Mercy Angiography Unit, Ltd. Mercy Hospital
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Otahuhu : Middlemore Hospital
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Norway
Ålesund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Elverum : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hamar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Harstad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hønefoss : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Lillehammer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Moss : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nesttun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oslo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sandefjord : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skedsmokorset : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Stavanger : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tønsberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Trondheim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tynset : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Poland
Bialystok : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Gdansk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gdynia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kraków : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Lódz : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
View More »
Olawa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Poznan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rumia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skierniewice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Warszawa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Warszawa : Novartis Investigative Site
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Wegrow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Puerto Rico
Manati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mayaguez : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ponce : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Juan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Romania
Baia Mare : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Braila : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brasov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucharest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucharest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Bucharest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj-Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Constanta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Craiova : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Craiova : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hunedoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Iasi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oradea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pitesti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sibiu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu-Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tg. Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Timisoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Timisoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Russian Federation
Barnaul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chelyabinsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ekaterinburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Izhevsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kemerovo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Kirov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Krasnodar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Moscow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Novosibirsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Omsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petrozavodsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ryazan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sankt-Peterburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saratov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sestroreck : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Smolensk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St.- Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St.-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tomsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tyumen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slovakia
Banska Bystrica : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bardejov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bratislava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bratislava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brezno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Dubnica nad Vahom : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dunajska Streda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Galanta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komarno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kosice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kosice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Levice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lucenec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nitra : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nove Zamky : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Povazska Bystrica : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Presov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Presov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rimavska Sobota : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rimavska Sobota : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Svidnik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Trnava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Velky Krtis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zilina : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Africa
Bloemfontein : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cape Town : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Durban : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Johannesburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pretoria : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Verwoerdburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Spain
Barcelona : Hospital Clinico Y Provincial
The OMEGA Clinical Trial
Lleida : Hospital Arnau de Vilanova
Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.
Sweden
Göteborg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kristianstad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Luleå : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Malmö : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Mölndal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Östersund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skanör : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skelleftea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skene : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Stockholm : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Uddevalla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vällingby : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Västerås : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Switzerland
Bern : University Hospital of Bern
The eMESH 1 Feasibility Study
Lausanne : Service de Chirurgie cardio-vasculaire CHUV
New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease
Taiwan
Changhua : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ilan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kaohsiung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lin-Ko : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Niaosong Township : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Taichung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taichung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taipei : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taipei : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Yungkang : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Turkey
Istanbul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
United Kingdom
Atherstone : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Axbridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Basingstoke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Birmingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bristol : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cardiff : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Carshalton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chesterfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dundee : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Exeter : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Glasgow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Irvine : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leicester : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
London : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Newcastle Upon Tyne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Newport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Newport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Norwich : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nottingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nottingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oxford : CTSU, University of Oxford
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
Penzance : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sheffield : Northern General Hospital
SuperNOVA Clinical Stenting Trial
West Midlands : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Whitby : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Worcester : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
York : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
